Oral inhibitor shows clinical activity in poor-prognosis AML

(Press-News.org) An oral targeted drug has shown encouraging activity and tolerable side effects in patients with treatment-resistant or relapsed acute myelogenous leukemia (AML) - a poor-prognosis group with few options - report investigators from Dana-Farber Cancer Institute and M.D. Anderson Cancer Center.   Of 32 patients treated with the oral inhibitor ABT-199, five had eradication of their leukemia and several more had stable disease, according to Anthony Letai, MD, PhD, of Dana-Farber, senior author of the report.     The phase 2 multicenter trial was the first use of ABT-199 in patients with relapsed or resistant AML. These patients often have received many previous treatments with chemotherapy or hypomethylating agents, and are too debilitated to undergo aggressive therapies such as more -intense chemotherapy or stem cell transplants.   The trial, involving 32 patients, was launched on the basis of preclinical studies from Letai's and Marina Konopleva's laboratories at Dana-Farber Cancer Institute and M.D. Anderson Cancer Center showing that ABT-199 could kill AML cell lines, patient AML cells, and patient-derived AML cells implanted into mice. ABT-199 targets the cancer "survival" protein BCL-2, which has been linked to resistance and poor prognosis in patients with AML.     Patients in the open-label trial ranged in age from 19 to 84 years and the median age was 71.   At the first assessment four weeks after treatment, one patient had a complete response and four had complete responses with incomplete recovery of normal blood cell forms; one of the four achieved a complete response by week 20, the investigators reported. Six of the 32 patient had at least a 50 percent reduction in bone marrow blasts.   No patients died as a result of adverse events from the treatment.   The researchers concluded that ABT-199 as a single agent "has considerable clinical activity in patients with poor-prognosis relapsed or resistant AML, and that patients with mutations in IDH genes may be particularly sensitive" to the drug.   Letai noted that that dose-limiting toxicity was not reached, leaving open the possibility of higher doses in further trials. The next step, he said, is to carry out trials combining ABT-199 with other agents.  These trials are currently opening at several sites, including at Dana-Farber.  

INFORMATION:

First author of the report is Marina Konopleva, MD, PhD, of the MD Anderson Cancer Center. Other authors are affiliated with Dana-Farber and Harvard Medical School, the University of Colorado Cancer Center, AbbVie, Inc., which makes ABT-199, and the Ohio State University Comprehensive Cancer Center.   Funding for the study was provided by AbbVie, Inc.